{"filing":{"accession_number":"0001654954-26-007894","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-08-27","report_date":"2026-08-27","primary_document":"a4036s.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426007894/a4036s.htm"},"events":[{"id":29891,"run_id":27386,"accession_number":"0001654954-26-007894","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This disclosure announces positive Phase III trial results for Tezspire (tezepelumab) in eosinophilic esophagitis, demonstrating statistically significant efficacy across co-primary and secondary endpoints at weeks 24 and 52. While the announcement describes clinical trial success rather than a discrete financial event, M\u0026A activity, or governance change, it represents a material operational and strategic milestone—successful Phase III data supporting potential regulatory approval and commercial expansion of a key pipeline asset into a third indication. This is material to investors assessing the company's pipeline value and growth prospects, though it does not fit neatly into the specific event categories (it is not an earnings release, which reports financial results; nor is it a restatement, impairment, or other financial accounting event). The operational domain is clear, making `operational_other` the most appropriate classification.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-08-27","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":32313,"accession_number":"0001654954-26-007894","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces positive Phase III trial results for Tezspire (tezepelumab) in eosinophilic esophagitis, demonstrating statistically significant efficacy across co-primary and secondary endpoints at weeks 24 and 52. While the announcement describes clinical trial success rather than a discrete financial event, M\u0026A activity, or governance change, it represents a material operational and strategic milestone—successful Phase III data supporting potential regulatory approval and commercial expansion of a key pipeline asset into a third indication. This is material to investors assessing the company's pipeline value and growth prospects, though it does not fit neatly into the specific event categories (it is not an earnings release, which reports financial results; nor is it a restatement, impairment, or other financial accounting event). The operational domain is clear, making `operational_other` the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-27T11:06:42.016401+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-08-27"}]}